Citations

Clear

626 citation(s) found for "Mehta, SH".

Diagnostic performance of the 0/2 hours ESC algorithm with high-sensitivity cardiac troponin T in an unselected community United States cohort
Ola, Oluwabukola Mary , Akula, Ashok , Knott, J D, Mehta, Roshni, Hodge, David O. , Tak, Tahir , Cagin, C, Gulati, R, Jaffe, Allan S. , Sandoval, Yader , Michieli, Laura De , Ola, O, Knott, Jonathan D , Mehta, R A, Jaffe, Allan S.

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.1458 Get It

Abstract Background There are no robust data addressing the United States (US) experience with the 0/2 hours (h) European Society of Cardiology (ESC) algorithm using high-sensitivity cardiac troponin T (hs-cTnT). Purpose To evaluate the diagnostic performance of the 0/2h ESC-recommended absolute deltas in a US population. Methods Observational US cohort study of ED patients undergoing 0 and 2 h hs-cTnT measurements. The 99th percentiles upper reference limits (URL) used were 10 ng/L for women and 15 ng/L for men. Diagnostic outcomes were the adjudicated diagnoses of acute myocardial infarction (MI, type 1 or 2). Results A total of 1084 patients met inclusion criteria, amongst which 49% were women. Chest discomfort was reported in 521 (48%) patients. Among patients with a baseline hs-cTnT≤99th URL (n=434), 4 MIs occurred. To rule-out MI, an absolute 0-2h delta change <4 ng/L resulted in a sensitivity of 100% (95% CI: 39.8, 100) and a negative predictive value (NPV) of 100% (95% CI: 99.1, 100). To rule-in MI, an absolute 0-2h delta ≥10 ng/L had a specificity of 99.8 % (95% CI: 98.7, 99.9) and positive predictive value (PPV) of 75% (95% CI: 19.4, 99.4). Among patients with a baseline hs-cTnT >99th URL (n=650), 110 MIs occurred. In these patients, both rule-out (sensitivity 65%, NPV 91%) and rule-in (specificity 7.2%, PPV 11%) were poor using the ESC-recommended absolute deltas. Among patients with modest hs-cTnT increases (99th URL to 100 ng/L) neither the ESC-recommended absolute nor the Fourth Universal Definition of MI (UDMI)-recommended relative deltas provided acceptable performance. Among patients with marked hs-cTnT increases at presentation (>100 ng/L), a relative delta change >20% as recommended by the UDMI resulted in a superior rule-in performance, with a specificity of 92.0% (95% CI 74.0, 99.0) and PPV of 84.6% (57.4, 95.7). Conclusions In our unselected US-cohort of patients undergoing hs-cTnT, the 0/2h ESC algorithm had a good diagnostic performance in patients without myocardial injury at presentation. Conversely, in patients with myocardial injury at baseline, the ESC-recommended absolute deltas performed poorly to determine who had MI. In patients with marked hs-cTnT increases >100 ng/L at presentation, the UDMI recommended 20% relative change showed good rule-in performance.
Does a high baseline high sensitivity cardiac troponin T allow for the early diagnosis of acute myocardial infarction?
Ola, Oluwabukola Mary , Akula, Ashok , Gharacholou, Michael, Lewis, B , Mehta, Ramila A. , Sandoval, Yader , Jaffe, Allan S. , Knott, J, Ola, O, Michieli, Laura De , Yang, Eric , Jaffe, Allan S.

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.1451 Get It

Abstract Background Guidelines suggest that the diagnosis of acute myocardial infarction (MI) is likely when high concentrations of high-sensitivity cardiac troponin (hs-cTn) are present in the initial sample. These concentration thresholds are much higher than the 99th percentile and are said to provide a high positive predictive value (PPV) for acute MI1. Purpose Evaluate the PPV of recommended baseline hs-cTnT thresholds (>52 and >100 ng/L) for the diagnosis of acute MI from our multi-center United States (US) experience. Methods Retrospective, multicenter (n=22), observational biomarker study involving consecutive, adult patients presenting to the emergency department (ED) in whom at least 1 hs-cTnT measurement was obtained within 12 hours of presentation (CV DataMart Biomarker cohort). The primary endpoint was also evaluated in an adjudicated cohort of consecutive patients presenting to the ED with at least 1 hs-cTnT >99th percentile (ACTION cohort). These cases were adjudicated based on the Fourth Universal Definition of MI by trained physicians. The primary efficacy endpoint was the PPV of acute MI (type 1 or 2), type 1 MI and type 2 MI during index hospitalization using baseline hs-cTnT thresholds of >52 ng/L and >100 ng/L. Results The CV DataMart Biomarker cohort consisted of 143,709 patients, amongst whom 3,003 (2.1%) were diagnosed with acute MI using ICD codes. In the CV DataMart Biomarker cohort, baseline hs-cTnT concentrations of >52 ng/L and >100 ng/L resulted in PPVs of 12% (95% CI: 11, 12) and 17% (95% CI: 17, 19) for acute MI, respectively. In patients with chest pain and baseline hs-cTnT concentrations >52 ng/L, PPV for acute MI was 17% (95% CI: 15, 18), and in those with hs-cTnT concentrations >100 ng/L, PPV was 22% (95% CI: 19, 25). The adjudicated ACTION cohort consisted of 2,107 patients, amongst whom 155 (7.4%) were diagnosed with acute MI including 64 (41%) with type 1 MI and 91 (59%) with type 2 MI. In the ACTION cohort, baseline hs-cTnT concentrations of >52 ng/L and >100 ng/L resulted in PPVs of 46% (95% CI: 40, 53) and 62% (95% CI: 53, 70) for acute MI, respectively. In patients with chest pain and baseline hs-cTnT concentrations >52 ng/L, PPV was 67% (95% CI: 57, 76) for acute MI, 52% (95% CI: 41, 62) for type 1 MI and 15% (95% CI: 8.4, 24) for type 2 MI. In those with chest pain and baseline hs-cTnT concentrations >100 ng/L, PPV was 77% (95% CI: 65, 87) for acute MI, 64% (95% CI: 51, 75) for type 1 MI and 14% (95% CI 6.4, 24) for type 2 MI (Figure). Conclusion Using previously recommended high-risk hs-cTnT thresholds of 52 and 100 ng/L in US patients provides reasonable performance to rule-in acute MI when used in patients with chest pain. When used more broadly across all-comers, the diagnostic performance is poor.
Cauda equina neuroendocrine tumors: A single institutional imaging review of cases over two decades
Ajmera, Pranav , Mehta, P. , Benson, John C. , Madhavan, Ajay A. , Bathla, Girish , Agarwal, Amit K, Mehta, Parv M, Benson, John , Madhavan, Ajay A , Diehn, Felix E. , Soni, Neetu , Bathla, Girish , Ajmera, Pranav , Mehta, Parv , Agarwal, Amit

Mayo Clinic

The Neuroradiology Journal | November 7, 2023 | Volume: 37 | Issue: 1 | Pages: 84-91

10.1177/19714009231212359 | PMID 37933451 Get It

Cauda Equina Neuroendocrine Tumors (CE-NET), previously referred to as paragangliomas are a rare subset of spinal tumors, with limited data on imaging. Herein, we present a retrospective review of clinical and imaging findings of CE-NETs in ten patients who were evaluated at our institution over the past two decades. All patients had well-defined intradural lesions in the lumbar spine which demonstrated slow growth. A review of imaging findings revealed the presence of an eccentric vascular pedicle along the dorsal aspect of the tumor in 8 of the 10 patients (eccentric vessel sign), a distinctive finding that has not previously been reported with this tumor and may help improve the accuracy of imaging-based diagnosis. In all cases, a gross-total resection was performed, with resolution of symptoms in most of the cases.
Breaking barriers: Effective interventions amplifying minority participation in cancer clinical trials.
Pottinger, David Lewis , Gaskin, Regan, Mehta, Amitkumar , Fouad, Mona N. , Niranjan, Soumya J , Desai, Aakash

Mayo Clinic

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 201-201

10.1200/op.2023.19.11_suppl.201 Get It

201 Background: Cancer-related mortality is disproportionately higher in marginalized populations, necessitating adequate representation in cancer clinical trials. Historically, this goal has been challenging, despite recognition of the importance for clinical practice. Moreover, minority recruitment has decreased in oncology clinical trials published from 2003-2016, indicating an urgent need for effective interventions for this issue. Methods: We conducted a systematic review of interventions focused on increasing minority recruitment/retention in cancer clinical trials between 2012-2023, or on improving attitudes of minority groups towards enrollment. We queried Embase and Scopus databases for articles/abstracts that focused on underrepresented ethnic minority enrollment in cancer clinical trials, in English language, were conducted in the US, Canada, Australia, New Zealand, or Western Europe, and were investigating effectiveness of interventions to improve minority enrollment in adult populations. Results: 261 unique articles/abstracts met our search criteria, with an additional 55 duplicates. 117 were removed for being irrelevant or too old, 31 for being reviews, 85 due to not containing an intervention, 5 for not reporting minority data, and 6 for not adequately comparing the strength of interventions. 17 met all inclusion criteria. Several interventions were identified, including targeted patient education (n=7), assigning patient navigators (n=6), community organization engagement (n=3), nested family/community approaches (n=2), and financial assistance (n=1). Targeted education involved video, audio, or interactive mediums. Most studies involved Black (n=12) and Hispanic (n=5) populations, with a smaller number focusing on Asian/Asian Pacific Islanders (n=2), Arabs (n=1), and Indian/South Asians (n=1). Geographically, these studies were notably concentrated in the American South (n=7). The Midwest and Mid-Atlantic regions contributed equally (n=3 each), and fewer studies were from the Northeast and West (n=2 each). Conclusions: Racial minorities continue to be underrepresented in cancer clinical trials, underscoring the need for concerted efforts to promote healthcare equity and enhance these trials’ generalizability. In our systematic review, targeted education, patient navigators, and active community engagement emerged as efficacious strategies, and were the most frequently utilized to bolster minority enrollment. Future studies should prioritize investigating and implementing these interventions, to ensure diverse, representative, and applicable clinical trial participation.
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson, James N. , Villa, Diego , Chapani, Parv , Li, Shaoying , Medeiros, L. Jeffrey , Wang, Michael , Cohen, Jonathon B. , Churnetski, Michael C. , Hill, Brian T. , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bachanová, Veronika , Kolla, Bhaskar , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Glenn, Martha, Inwards, David J. , Ristow, Kay M., Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Villa, Diego , Gerrie, Alina S , Chapani, Parv , Li, Shaoying , Medeiros, L Jeffrey , Wang, Michael L , Sawalha, Yazeed , Vose, Julie , Bond, David A , Kolla, Bhaskar , Lansigan, Frederick , Wagner-Johnston, Nina , Messmer, Marcus , Mehta, Amitkumar , Ristow, Kay, Karmali, Reem , Caimi, Paolo F , Evens, Andrew M , Amengual, Jennifer E , Bachanova, Veronika , Diefenbach, Catherine S , Handorf, Elizabeth A. , Gerrie, Alina S. , Sawalha, Yazeed , Vose, Julie M. , Bond, David A. , Chavez, Julio C , Shah, Bijal , Lansigan, Frederick , Burns, Timothy Francis , Mehta, Amitkumar , Kovach, Alexandra E. , Landsburg, Daniel J. , Karmali, Reem , Kaplan, Jason , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Blood Advances | October 24, 2023 | Volume: 7 | Issue: 24 | Pages: 7393-7401

10.1182/bloodadvances.2023010757 | PMID 37874912 Get It

Abstract Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
Rationale for the Development of a Novel Clinical Grading Scale for Postoperative Facial Nerve Function: Results of a Multidisciplinary International Working Group
Carlson, Matthew L. , Lohse, Christine M. , Babu, Seilesh C. , Barker, Frederick G., Barnett, Samuel , Biggs, Nigel, Boahene, Kofi , Breen, Joseph T. , Brown, Kevin D. , Cayé‐Thomasen, Per , Cosetti, Maura K. , Deep, Nicholas L. , Dornhoffer, James R. , Forner, David , Hansen, Marlan R. , Kalamarides, Michel , Kim, Irene A., Kircher, Matthew L., Link, Michael J., Lloyd, Simon , Lund‐Johansen, Morten , Marinelli, John P. , Matthies, Cordula , Moore, Eric J. , Nassiri, Ashley M. , Neff, Brian A., Patel, Neil S. , Celda, María Peris, Plitt, Aaron , Sweeney, Alex D. , Tasche, Kendall K. , Tatagiba, Marcos , Tveiten, Øystein Vesterli , Vrabec, Jeffrey T. , Wanna, George B. , Weisskopf, Peter A., Tatagiba, Marcos , Agazzi, Siviero , Bi, Wenya Linda , Dey, Jacob K. , Gurgel, Richard Klaus , Hunter, Jacob B. , King, Andrew Thomas , Lassaletta, Luis , Mehta, Vikas , Nelson, Rick F , Olson, Jeffrey J. , Price, Daniel L. , Roland, J. Thomas , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 44 | Issue: 10 | Pages: e747-e754

10.1097/mao.0000000000004039 | PMID 37875014 Get It

Objective The objective of the current study was to present the results of an international working group survey identifying perceived limitations of existing facial nerve grading scales to inform the development of a novel grading scale for assessing early postoperative facial paralysis that incorporates regional scoring and is anchored in recovery prognosis and risk of associated complications. Study Design Survey. Setting A working group of 48 multidisciplinary clinicians with expertise in skull base, cerebellopontine angle, temporal bone, or parotid gland surgery. Results House-Brackmann grade is the most widely used system to assess facial nerve function among working group members (81%), although more than half (54%) agreed that the system they currently use does not adequately estimate the risk of associated complications, such as corneal injury, and confidence in interrater and intrarater reliability is generally low. Simplicity was ranked as the most important attribute of a novel postoperative facial nerve grading system to increase the likelihood of adoption, followed by reliability and accuracy. There was widespread consensus (91%) that the eye is the most critical facial region to focus on in the early postoperative setting. Conclusions Members were invited to submit proposed grading systems in alignment with the objectives of the working group for subsequent validation. From these data, we plan to develop a simple, clinically anchored, and reproducible staging system with regional scoring for assessing early postoperative facial nerve function after surgery of the skull base, cerebellopontine angle, temporal bone, or parotid gland.
S562 Addressing Diagnostic Dilemmas in Eosinophilic Esophagitis Using Esophageal Epithelial Eosinophilic-Derived Neurotoxin
Thomas, Jessina, Hopson, Puanani , Deb, Chirajyoti , Bornstein, Jeffrey D. , Mehta, Devendra I. , Bittar, Khaled, Smadi, Yamen

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S411-S412

10.14309/01.ajg.0000951888.49608.68 Get It

Treatment of intramedullary spinal cord tumors: a modified Delphi technique of the North American Spine Society Section of Spine Oncology
Pennington, Zach , Elsamadicy, Aladine A. , Dea, Nicolas , Desai, Atman , Gokaslan, Ziya L. , Hsu, Wesley , Krishnaney, Ajit A., Laufer, Ilya , Lo, Sheng-Fu Larry , Macki, Mohamed, Mehta, Ankit I. , Ozturk, Ali K. , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew M. , Lubelski, Daniel , Goodwin, C. Rory , Jallo, George I. , Shin, John H. , Soliman, Hesham Magdi

Mayo Clinic

Journal of Neurosurgery: Spine | October 13, 2023 | Volume: 40 | Issue: 1 | Pages: 1-10

10.3171/2023.8.spine23190 | PMID 37856379 Get It

OBJECTIVE Intramedullary spinal cord tumors (IMSCTs) are rare tumors with heterogeneous presentations and natural histories that complicate their management. Standardized guidelines are lacking on when to surgically intervene and the appropriate aggressiveness of resection, especially given the risk of new neurological deficits following resection of infiltrative tumors. Here, the authors present the results of a modified Delphi method using input from surgeons experienced with IMSCT removal to construct a framework for the operative management of IMSCTs based on the clinical, radiographic, and tumor-specific characteristics. METHODS A modified Delphi technique was conducted using a group of 14 neurosurgeons experienced in IMSCT resection. Three rounds of written correspondence, surveys, and videoconferencing were carried out. Participants were queried about clinical and radiographic criteria used to determine operative candidacy and guide decision-making. Members then completed a final survey indicating their choice of observation or surgery, choice of resection strategy, and decision to perform duraplasty, in response to a set of patient- and tumor-specific characteristics. Consensus was defined as ≥ 80% agreement, while responses with 70%–79% agreement were defined as agreement. RESULTS Thirty-six total characteristics were assessed. There was consensus favoring surgical intervention for patients with new-onset myelopathy (86% agreement), chronic myelopathy (86%), or progression from mild to disabling numbness (86%), but disagreement for patients with mild numbness or chronic paraplegia. Age was not a determinant of operative candidacy except among frail patients, who were deemed more suitable for observation (93%). Well-circumscribed (93%) or posteriorly located tumors reaching the surface (86%) were consensus surgical lesions, and participants agreed that the presence of syringomyelia (71%) and peritumoral T2 signal change (79%) were favorable indications for surgery. There was consensus that complete loss of transcranial motor evoked potentials with a 50% decrease in the D-wave amplitude should halt further resection (93%). Preoperative symptoms seldom influenced choice of resection strategy, while a distinct cleavage plane (100%) or visible tumor-cord margins (100%) strongly favored gross-total resection. CONCLUSIONS The authors present a modified Delphi technique highlighting areas of consensus and agreement regarding surgical management of IMSCTs. Although not intended as a substitute for individual clinical decision-making, the results can help guide care of these patients. Additionally, areas of controversy meriting further investigation are highlighted.
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials
Walter, Angela Wangari , Lee, Ju‐Whei, Gareen, Ilana F. , Herman, B. , Kircher, Sheetal Mehta , Carlos, Ruth C. , Kumar, Shaji , Saba, Nabil F. , Fenske, Timothy S. , Neal, Joel W. , Hodi, Frank S., Kyriakopoulos, Christos E. , Tempany, Clare M. , Shanafelt, Tait D. , Kircher, Sheetal M , Carlos, Ruth , Kumar, Shaji K , Saba, Nabil F , Neal, Joel W , Wagner, Lynne , Ostroff, Jamie S , Park, Elyse R , Shanafelt, Tait D , Lee, Ju‐Whei , Streck, Joanna M. , Mayer, Ingrid A. , Atkins, Michael B. , Wagner, Lynne I. , Land, Stephanie R

Mayo Clinic

Cancer | October 5, 2023 | Volume: 130 | Issue: 3 | Pages: 439-452

10.1002/cncr.35039 | PMID 37795845 Get It

AbstractBackgroundTobacco use is associated with adverse outcomes among patients diagnosed with cancer. Socioeconomic determinants influence access and utilization of tobacco treatment; little is known about the relationship between neighborhood socioeconomic disadvantage (NSD) and tobacco assessment, assistance, and cessation among patients diagnosed with cancer.MethodsA modified Cancer Patient Tobacco Use Questionnaire (C‐TUQ) was administered to patients enrolled in nine ECOG‐ACRIN clinical trials. We examined associations of NSD with (1) smoking status, (2) receiving tobacco cessation assessment and support, and (3) cessation behaviors. NSD was classified by tertiles of the Area Deprivation Index. Associations between NSD and tobacco variables were evaluated using logistic regression.ResultsA total of 740 patients completing the C‐TUQ were 70% male, 94% White, 3% Hispanic, mean age 58.8 years. Cancer diagnoses included leukemia 263 (36%), lymphoma 141 (19%), prostate 131 (18%), breast 79 (11%), melanoma 69 (9%), myeloma 53 (7%), and head and neck 4 (0.5%). A total of 402 (54%) never smoked, 257 (35%) had formerly smoked, and 81 (11%) were currently smoking. Patients in high disadvantaged neighborhoods were approximately four times more likely to report current smoking (odds ratio [OR], 3.57; 95% CI, 1.69–7.54; p = .0009), and more likely to report being asked about smoking (OR, 4.24; 95% CI, 1.64–10.98; p = .0029), but less likely to report receiving counseling (OR, 0.11; 95% CI, 0.02–0.58; p = .0086) versus those in the least disadvantaged neighborhoods.ConclusionsGreater neighborhood socioeconomic disadvantage was associated with smoking but less cessation support. Increased cessation support in cancer care is needed, particularly for patients from disadvantaged neighborhoods.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
Wen, Patrick Y. , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Barboriak, Daniel P. , Groot, John de , Huang, Raymond Y. , Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Macdonald, David R., Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , van den Bent, Martin J , Weller, Michael , Barboriak, Daniel P , de Groot, John , Huang, Raymond , Lassman, Andrew B , Mehta, Minesh P , Molinaro, Annette M. , Preusser, Matthias , Rahman, Rifaquat , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang , Reardon, David A , Vogelbaum, Michael A , Ellingson, Benjamin M , Cloughesy, Timothy F , Wen, Patrick Yung , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Preusser, Matthias , Stupp, Roger , Wick, Wolfgang

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 33 | Pages: 5187-5199

10.1200/jco.23.01059 | PMID 37774317 Get It

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION The revised RANO 2.0 criteria refine response assessment in gliomas.